The Unresolved Role of Interferon-λ in Asthma Bronchiale

Department of Molecular Pneumology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Germany

Asthma bronchiale is a disease of the airways with increasing incidence, that often begins during infancy. So far, therapeutic options are mainly symptomatic and thus there is an increasing need for better treatment and/or prevention strategies. Human rhinoviruses (HRVs) are a major cause of asthma exacerbations and might cause acute wheezing associated with local production of pro-inflammatory mediators resulting in neutrophilic inflammatory response. Viral infections induce a characteristic activation of immune response, e.g., TLR3, 4, 7, 8, 9 in the endosome and their downstream targets, especially MyD88. Moreover, other cytoplasmic pattern recognition molecules (PRMs) like RIG1 and MDA5 play important roles in the activation of interferons (IFNs) of all types. Depending on the stimulation of the different PRMs, the levels of the IFNs induced might differ. Recent studies focused on Type I IFNs in samples from control and asthma patients. However, the administration of type I IFN-α was accompanied by side-effects, thus this possible therapy was abandoned. Type III IFN-λ acts more specifically, as fewer cells express the IFN-λ receptor chain 1. In addition, it has been shown that asthmatic mice treated with recombinant or adenoviral expressed IFN-λ2 (IL–28A) showed an amelioration of symptoms, indicating that treatment with IFN-λ might be beneficial for asthmatic patients.

 
Download Article (PDF)         Full text (html) 
 

 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: “JAK Inhibitors Showing Promise for Many Skin Problems Conditions ranging from alopecia to vitiligo” https://t.co/mSR0or0JM5
6hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: Carina Venter PhD RD on Twitter: "A few months ago Cat’s in the Crad… https://t.co/hSf86Y42Qo, see more https://t.…
6hreplyretweetfavorite
Interasma RT @Aller_MD: “Mechanistic insights on topical tacrolimus for the treatment of atopic dermatitis” https://t.co/YFs34eAADf https://t.co/UZMa
6hreplyretweetfavorite
Interasma RT @Aller_MD: Upper and lower airway remodelling mechanisms in #asthma, #allergic rhinitis and chronic #rhinosinusitis: the one airway conc…
6hreplyretweetfavorite
Interasma RT @Aller_MD: Hot Topics: Recent Developments in Dermatologic Therapies https://t.co/w5mnT5B566 https://t.co/Vj5jJmgoO6
11hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma